Menu
Search
|

Menu

Close
X

DelMar Pharmaceuticals Inc DMPI.OQ (NASDAQ Stock Exchange Capital Market)

0.64 USD
-- (--)
As of Jul 17
chart
Previous Close 0.64
Open --
Volume --
3m Avg Volume 34,302
Today’s High --
Today’s Low --
52 Week High 2.83
52 Week Low 0.63
Shares Outstanding (mil) 22.01
Market Capitalization (mil) 14.64
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.450
FY17
-0.735
FY16
-0.829
FY15
-0.477
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
19.57
Price to Sales (TTM)
vs sector
--
6.06
Price to Book (MRQ)
vs sector
12.53
2.83
Price to Cash Flow (TTM)
vs sector
--
26.07
Total Debt to Equity (MRQ)
vs sector
0.00
63.83
LT Debt to Equity (MRQ)
vs sector
0.00
32.05
Return on Investment (TTM)
vs sector
-252.92
0.53
Return on Equity (TTM)
vs sector
--
16.53

EXECUTIVE LEADERSHIP

Robert Hoffman
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Saiid Zarrabian
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Scott Praill
Chief Financial Officer, Since 2013
Salary: $240,000.00
Bonus: $40,000.00
Dennis Brown
Chief Scientific Officer, Director, Since 2013
Salary: $175,000.00
Bonus: $40,000.00
John Bell
Lead Independent Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Financials
Industry: Holding Companies
Address:

999 Broadway W Suite 720
VANCOUVER   BC   V5Z 1K5

Phone: +1604.6295989

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

SPONSORED STORIES